<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04260945</url>
  </required_header>
  <id_info>
    <org_study_id>HXYT-007</org_study_id>
    <nct_id>NCT04260945</nct_id>
  </id_info>
  <brief_title>CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients</brief_title>
  <official_title>CD19/CD20 Dual-CAR-T for Patients With B-cell Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Yanda Ludaopei Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>China Immunotech (Beijing) Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hebei Yanda Ludaopei Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, single arm, open-label, phase I study to evaluate the safety and&#xD;
      efficacy of CD19/CD20 Dual-CAR-T cells in patients with refractory and relapsed B-cell&#xD;
      leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase I study is designed as a pilot trial evaluating the safety and efficacy of&#xD;
      CD19/CD20 Dual-CAR-T cell therapy in subjects with refractory and relapsed B cell leukemia.&#xD;
      Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on&#xD;
      days -5, -4 and -3 followed by infusion of CD19/CD20 Dual-CAR-T cells. Safety and efficacy of&#xD;
      CD19/CD20 Dual-CAR-T cells therapy will be monitored. The purpose of current study is to&#xD;
      determine the clinical efficacy and safety of CD19/CD20 Dual-CAR-T cells therapy in patients&#xD;
      with refractory and relapsed B-cell leukemia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2020</start_date>
  <completion_date type="Anticipated">November 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 10, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with adverse events.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective remission rate(ORR)</measure>
    <time_frame>6 months</time_frame>
    <description>The percentage of participants who achieved complete remission (CR) and partial remission over all participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse-Free Survival(RFS )</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall-Survival(OS)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of CAR-T cells in vivo</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>B-cell Leukemia</condition>
  <arm_group>
    <arm_group_label>CD19/CD20 Dual-CAR-T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD19/CD20 Dual-CAR-T cells</intervention_name>
    <description>CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 0.6-3×106 cells/kg.</description>
    <arm_group_label>CD19/CD20 Dual-CAR-T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Relapsed and refractory B-cell acute malignancies with:&#xD;
&#xD;
               -  Relapsed after competed remission, could not get competed remission after at more&#xD;
                  than 1 course of chemotherapy (including MRD≥0.1%);&#xD;
&#xD;
               -  MRD≥0.1% after allogeneic hematopoietic stem cell transplantation(HSCT), or&#xD;
                  recurrence after complete remission or MRD ≥ 0.1% after HSCT;&#xD;
&#xD;
               -  Refractory: at least two courses of chemotherapy did not achieve complete&#xD;
                  remission or MRD ≥ 0.1%;&#xD;
&#xD;
          2. Patients must have evaluable evidence of disease, including minimal residual disease&#xD;
             (MRD);&#xD;
&#xD;
          3. Ph + patients who meet the following criteria can register:Failure to tolerate TKI or&#xD;
             TKI treatment failure, or failure to transplant;&#xD;
&#xD;
          4. Double positive expression of CD19 / CD20 in B cells;&#xD;
&#xD;
          5. Ages 1 to 70 years, including boundary values;&#xD;
&#xD;
          6. ECOG score 0-3 points;&#xD;
&#xD;
          7. Women of childbearing age (15-49 years old) must receive a pregnancy test within 7&#xD;
             days prior to initiation of treatment and the results are negative; male and female&#xD;
             patients with fertility must use an effective contraceptive to ensure 3 months after&#xD;
             discontinuation of treatment during the study period not pregnant inside.&#xD;
&#xD;
          8. Patients who voluntarily sign informed consent and are willing to comply with&#xD;
             treatment plans.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. patients with organ failure:&#xD;
&#xD;
               -  Heart: NYHA heart function grade IV;&#xD;
&#xD;
               -  Liver: Grade C that achieves Child-Turcotte liver function grading;&#xD;
&#xD;
               -  Kidney: kidney failure and uremia;&#xD;
&#xD;
               -  Lung: symptoms of respiratory failure;&#xD;
&#xD;
               -  Brain: a person with a disability;&#xD;
&#xD;
          2. Active infections that are difficult to control;&#xD;
&#xD;
          3. Human immunodeficiency virus (HIV) positive;&#xD;
&#xD;
          4. Liver and kidney function: total bilirubin &gt; 5 × ULN, aspartate aminotransferase (AST)&#xD;
             and alanine aminotransferase (ALT) &gt; 5 × ULN, serum creatinine clearance rate 60mL /&#xD;
             min;&#xD;
&#xD;
          5. GVHD ≥ 2 or anti-GVHD treatment;&#xD;
&#xD;
          6. Received allogeneic cell therapy within 4 weeks, such as donor lymphocyte infusion;&#xD;
&#xD;
          7. Subject received anti-tumor treatment (chemotherapy, mAb, or hormone) for less than 1&#xD;
             week;&#xD;
&#xD;
          8. Central nervous system white blood that is symptomatic or uncontrolled by systemic&#xD;
             chemotherapy and intrathecal chemotherapy (a large number of tumor cells in CSF, white&#xD;
             blood cell count &gt;15WBCs/mL);&#xD;
&#xD;
          9. intracranial hypertension or unconsciousness; respiratory failure; diffuse vascular&#xD;
             internal coagulation;&#xD;
&#xD;
         10. pregnant or lactating women;&#xD;
&#xD;
         11. The patient does not agree to use effective contraception during the treatment period&#xD;
             and for the next 3 months;&#xD;
&#xD;
         12. Patients who participate in other clinical studies at the same time;&#xD;
&#xD;
         13. The investigator believes that there are other factors that are not suitable for&#xD;
             inclusion or influence the subject's participation or completion of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xian Zhang, PhD</last_name>
    <phone>010-80841201</phone>
    <email>zhxian2@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hebei Yanda Ludaopei Hospital</name>
      <address>
        <city>Sanhe</city>
        <state>Hebei</state>
        <zip>065200</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xian Zhang, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>February 6, 2020</study_first_submitted>
  <study_first_submitted_qc>February 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2020</study_first_posted>
  <last_update_submitted>August 9, 2020</last_update_submitted>
  <last_update_submitted_qc>August 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, B-Cell</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

